OSI-7904L and Oxaliplatin in Treating Patients With Refractory or Recurrent Advanced Colorectal Cancer
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: OSI-7904L may stop the growth of tumor cells by blocking the enzymes necessary for
their growth. Drugs used in chemotherapy, such as oxaliplatin, work in different ways to stop
tumor cells from dividing so they stop growing or die. Combining OSI-7904L with oxaliplatin
may kill more tumor cells.
PURPOSE: This phase I trial is studying the side effects and best dose of OSI-7904L and
oxaliplatin in treating patients with refractory or recurrent advanced colorectal cancer.
Phase:
Phase 1
Details
Lead Sponsor:
European Organisation for Research and Treatment of Cancer - EORTC